Search the webpage

Created by Leona Damalakienė on   July 25, 2019   in category: News

Experimentica Ltd. revealed its strategic plan that outlines a roadmap for the development of artificial intelligence (AI)-based algorithms aimed at quantifying and predicting the preclinical efficacy and safety of next-generation drugs for ophthalmic indications.

The strategic roadmap includes a €3,05 million investment, which is supported in part by a competitive award “Intellect. Business and research cooperation projects” received under the “Promotion of Scientific Research, Experimental Development and Innovations Priority of the Operational Programme of the European Union Structural Funds for 2014-2020”.

 

 

We are pleased and honored to receive EU funding support for the implementation of our AI-based platform for preclinical research. Since Experimentica’s inception in 2013, our strategy was to combine state-of-the-art technology with our scientific expertise and know-how in order to advance and accelerate the preclinical pipelines of pharma and biotech companies. This business model has positioned Experimentica as a global leader in the ophthalmic CRO market. Our next goal is to introduce AI-based prediction of drug efficacy and safety, which will shape the CRO industry already in the near future”, said Dr. Giedrius Kalesnykas, Founder and Chief Executive Officer of the company.

Our continued investment into development of novel technological approaches will sustain Experimentica’s role as industry leader and position us to be at the forefront of model development for the preclinical testing of ophthalmic drug candidates for our clients. Combining artificial intelligence with traditional preclinical testing will offer new opportunities for therapeutic development for the many complex and debilitating ophthalmic indications”, added Dr. Simon Kaja, Chief Scientific Officer of Experimentica.

 

About Experimentica Ltd.


Experimentica Ltd. is a global contract research organization (CRO) that specializes in preclinical models for ophthalmic indications. The world class scientists and technicians apply a comprehensive set of skills on various in vitro, ex vivo and in vivo modelling platforms. With proprietary laboratories in Kuopio, Finland and Vilnius, Lithuania alongside a global representation, Experimentica Ltd. delivers the highest quality science in preclinical ophthalmic drug discovery.

 

Contact for media enquiries:

Dr. Leona Damalakiene
R&D Director
Experimentica Ltd.
Phone: +370 (686) 14 280
Email: leona@experimentica.com

LATEST NEWS

Experimentica Ltd. presents strategic roadmap and announces €3,05M investment in artificial intelligence for preclinical efficacy and safety testing of ophthalmic drug candidates

News
Experimentica Ltd. revealed its strategic plan that outlines a roadmap for the development of artificial intelligence (AI)-based algorithms aimed at ... Read More

Experimentica Ltd. participates in ORBITAL, an EU Horizon 2020 Marie Sklodowska-Curie Innovative Training Network award

News
Experimentica Ltd. is pleased to announce its participation as beneficiary in EU Horizon 2020 Marie Sklodowska-Curie Innovative Training Network award ... Read More

A retinal organotypic model for ex vivo neuroprotection studies

News
A recently published study by Experimentica Ltd. and its collaborators from the University of Tampere, Finland, shows that when the ... Read More

Subscribe to Our Newsletter!

We promise that no sales pitches will be attached to newsletter. And don't worry, we hate spammers too!